242 related articles for article (PubMed ID: 34323123)
1. Clinical Outcomes of Very Elderly Patients With Atrial Fibrillation Receiving On-label Doses of Apixaban: J-ELD AF Registry Subanalysis.
Okada M; Inoue K; Tanaka N; Sakata Y; Akao M; Yamashita T; Suzuki S; Okumura K;
J Am Heart Assoc; 2021 Aug; 10(15):e021224. PubMed ID: 34323123
[TBL] [Abstract][Full Text] [Related]
2. A multicenter prospective cohort study to investigate the effectiveness and safety of apixaban in Japanese elderly atrial fibrillation patients (J-ELD AF Registry).
Okumura K; Yamashita T; Suzuki S; Akao M;
Clin Cardiol; 2020 Mar; 43(3):251-259. PubMed ID: 31737921
[TBL] [Abstract][Full Text] [Related]
3. Impact of creatinine clearance on clinical outcomes in elderly atrial fibrillation patients receiving apixaban: J-ELD AF Registry subanalysis.
Akao M; Yamashita T; Suzuki S; Okumura K;
Am Heart J; 2020 May; 223():23-33. PubMed ID: 32135338
[TBL] [Abstract][Full Text] [Related]
4. Association of Low Body Weight with Clinical Outcomes in Elderly Atrial Fibrillation Patients Receiving Apixaban-J-ELD AF Registry Subanalysis.
Kadosaka T; Nagai T; Suzuki S; Sakuma I; Akao M; Yamashita T; Anzai T; Okumura K;
Cardiovasc Drugs Ther; 2022 Aug; 36(4):691-703. PubMed ID: 33830400
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes according to dose reduction criteria of apixaban in Japanese elderly patients with atrial fibrillation: J-ELD AF Registry subanalysis.
Akao M; Yamashita T; Suzuki S; Okumura K;
Heart Vessels; 2021 Jul; 36(7):1035-1046. PubMed ID: 33486555
[TBL] [Abstract][Full Text] [Related]
6. Clinical implications of assessment of apixaban levels in elderly atrial fibrillation patients: J-ELD AF registry sub-cohort analysis.
Suzuki S; Yamashita T; Akao M; Okumura K;
Eur J Clin Pharmacol; 2020 Aug; 76(8):1111-1124. PubMed ID: 32451850
[TBL] [Abstract][Full Text] [Related]
7. Secondary stroke prevention with apixaban in nonvalvular atrial fibrillation: A subgroup analysis of the STANDARD study.
Yasaka M; Umeyama M; Kataoka H; Inoue H
J Stroke Cerebrovasc Dis; 2020 Sep; 29(9):105034. PubMed ID: 32807446
[TBL] [Abstract][Full Text] [Related]
8. Apixaban for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: The PAROS cross-sectional study of routine clinical practice.
Falissard B; Picard F; Mahe I; Hanon O; Touzé E; Danchin N; Lamy FX; Ricci L; Steg PG
Arch Cardiovasc Dis; 2019; 112(6-7):400-409. PubMed ID: 31014991
[TBL] [Abstract][Full Text] [Related]
9. Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study.
Rutherford OW; Jonasson C; Ghanima W; Söderdahl F; Halvorsen S
Eur Heart J Cardiovasc Pharmacother; 2020 Apr; 6(2):75-85. PubMed ID: 31942972
[TBL] [Abstract][Full Text] [Related]
10. Off-label reduced-dose apixaban does not reduce hemorrhagic risk in Taiwanese patients with nonvalvular atrial fibrillation: A retrospective, observational study.
Chen IC; Chang WT; Hsu PC; Yeh YL; Zheng S; Huang YC; Lin CH; Tsai LM; Lin LJ; Liu PY; Liu YW
Medicine (Baltimore); 2021 Jun; 100(23):e26272. PubMed ID: 34115024
[TBL] [Abstract][Full Text] [Related]
11. Age-Related Differences in the Clinical Characteristics and Treatment of Elderly Patients With Atrial Fibrillation in Japan - Insight From the ANAFIE (All Nippon AF In Elderly) Registry.
Hiasa KI; Kaku H; Inoue H; Yamashita T; Akao M; Atarashi H; Koretsune Y; Okumura K; Shimizu W; Ikeda T; Toyoda K; Hirayama A; Yasaka M; Yamaguchi T; Teramukai S; Kimura T; Kaburagi J; Takita A; Tsutsui H
Circ J; 2020 Feb; 84(3):388-396. PubMed ID: 31969518
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Treatment with Apixaban in Patients with Atrial Fibrillation: Outcomes during the Open-Label Extension following AVERROES.
Benz AP; Eikelboom JW; Yusuf S; Hohnloser SH; Kahl A; Beresh H; Balasubramanian K; Healey JS; Connolly SJ
Thromb Haemost; 2021 Apr; 121(4):518-528. PubMed ID: 33011964
[TBL] [Abstract][Full Text] [Related]
13. Study design of J-ELD AF: A multicenter prospective cohort study to investigate the efficacy and safety of apixaban in Japanese elderly patients.
Akao M; Yamashita T; Okumura K;
J Cardiol; 2016 Dec; 68(6):554-558. PubMed ID: 26803550
[TBL] [Abstract][Full Text] [Related]
14. Stroke and Bleeding Risks in Patients with Atrial Fibrillation Treated with Reduced Apixaban Dose: A Real-Life Study.
Salameh M; Gronich N; Stein N; Kotler A; Rennert G; Auriel E; Saliba W
Clin Pharmacol Ther; 2020 Dec; 108(6):1265-1273. PubMed ID: 32558928
[TBL] [Abstract][Full Text] [Related]
15. Off-Label Reduced Dose Apixaban in Older Adults With Atrial Fibrillation and Associated Outcomes.
Campbell AM; Pae E; Lee E; Jacisin T; Price A; DeAngelo J
Ann Pharmacother; 2024 Jun; 58(6):572-580. PubMed ID: 37712551
[TBL] [Abstract][Full Text] [Related]
16. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes.
Hylek EM; Held C; Alexander JH; Lopes RD; De Caterina R; Wojdyla DM; Huber K; Jansky P; Steg PG; Hanna M; Thomas L; Wallentin L; Granger CB
J Am Coll Cardiol; 2014 May; 63(20):2141-2147. PubMed ID: 24657685
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation.
Martinez BK; Sood NA; Bunz TJ; Coleman CI
J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29654196
[TBL] [Abstract][Full Text] [Related]
18. Safety and effectiveness of apixaban in comparison to warfarin in patients with nonvalvular atrial fibrillation: a propensity-matched analysis from Japanese administrative claims data.
Kohsaka S; Katada J; Saito K; Terayama Y
Curr Med Res Opin; 2018 Sep; 34(9):1627-1634. PubMed ID: 29772946
[TBL] [Abstract][Full Text] [Related]
19. Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial.
Pol T; Held C; Westerbergh J; Lindbäck J; Alexander JH; Alings M; Erol C; Goto S; Halvorsen S; Huber K; Hanna M; Lopes RD; Ruzyllo W; Granger CB; Hijazi Z
J Am Heart Assoc; 2018 Feb; 7(3):. PubMed ID: 29419390
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of Apixaban-Treated Patients, Evaluation of the Dose Prescribed, and the Persistence of Treatment: A Cohort Study in Catalonia.
Gomez-Lumbreras A; Cortes J; Giner-Soriano M; Quijada-Manuitt MA; Morros R
J Cardiovasc Pharmacol Ther; 2018 Nov; 23(6):494-501. PubMed ID: 29792125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
